Search Within

Hira Abbas Rizvi

Formats
  1. Journal Article (65)
  2. Meeting Abstract (58)
Groups
  1. Department of Medicine (123)
  2. Solid Tumor Oncology Division (123)
  3. Thoracic Oncology (121)
  4. Hematology-Oncology Fellows (81)
  5. GSK Faculty (67)
  6. Weinberg Fellows (67)

More Groups

People
  1. Matthew Hellmann (97)
  2. Gregory Riely (42)
  3. Andrew Plodkowski (41)
  4. Charles Rudin (37)
  5. Mark Kris (34)
  6. Kathryn Arbour (32)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (8)
  4. 2022 (17)
  5. 2021 (23)
  6. 2020 (25)

More Years

Publications
  1. Journal of Clinical Oncology (35)
  2. Journal of Thoracic Oncology (16)
  3. Annals of Oncology (12)
  4. Clinical Cancer Research (12)
  5. Cancer Research (10)
  6. Cancer Cell (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (37)
  2. American Association for Cancer Research (28)
  3. Elsevier Inc. (20)
  4. Oxford University Press (13)
  5. Cell Press (7)
  6. American Medical Association (4)

More Publishers

Results (123)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Inter-test variability in tumor mutational burden (TMB) quantification and identification of TMB thresholds
    Meeting Abstract

    Vokes, N.; Alguilar, E. J.; Umeton, R.; Adeni, A.; Sholl, L.; Hellmann, M.; Rizvi, H.; Awad, M.; Van Allen, E.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Acute lung injury pattern is a frequent histologic finding in lung tissue following immune checkpoint inhibitor therapy
    Meeting Abstract

    Golden, A.; Imran, S.; Feinstein, M.; Hellmann, M.; Plodkowski, A.; Rekhtman, N.; Rizvi, H.; Travis, W.; Stover, D.; Sauter, J.
    Modern Pathology (2019)

    Fulltext@MSK | Save
  • Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
    Journal Article

    Schoenfeld, A. J.; Arbour, K. C.; Rizvi, H.; Iqbal, A. N.; Gadgeel, S. M.; Girshman, J.; Kris, M. G.; Riely, G. J.; Yu, H. A.; Hellmann, M. D.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes
    Journal Article

    Offin, M.; Chan, J. M.; Tenet, M.; Rizvi, H. A.; Shen, R.; Riely, G. J.; Rekhtman, N.; Daneshbod, Y.; Quintanal-Villalonga, A.; Penson, A.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Acute lung injury pattern is a frequent histologic finding in lung tissue following immune checkpoint inhibitor therapy
    Meeting Abstract

    Golden, A.; Imran, S.; Feinstein, M.; Hellmann, M.; Plodkowski, A.; Rekhtman, N.; Rizvi, H.; Travis, W.; Stover, D.; Sauter, J.
    Laboratory Investigation (2019)

    Fulltext@MSK | Save
  • Tumor characteristics associated with benefit from pembrolizumab in advanced non–small cell lung cancer
    Journal Article

    Hu-Lieskovan, S.; Lisberg, A.; Zaretsky, J. M.; Grogan, T. R.; Rizvi, H.; Wells, D. K.; Carroll, J.; Cummings, A.; Madrigal, J.; Jones, B.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers
    Journal Article

    Offin, M.; Rizvi, H.; Tenet, M.; Ni, A.; Sanchez-Vega, F.; Li, B. T.; Drilon, A.; Kris, M. G.; Rudin, C. M.; Schultz, N.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Clinical and molecular features predicting long-term response (LTR) to anti-PD-(L)1 based therapy in patients with NSCLC
    Meeting Abstract

    Rizvi, H.; Plodkowski, A. J.; Tenet, M.; Halpenny, D.; Long, N.; Sauter, J. L.; Sanchez-Vega, F.; Chatila, W. K.; Schultz, N.; Ladanyi, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Tumor mutation burden and efficacy of targeted therapy in patients with EGFR mutant lung cancers
    Meeting Abstract

    Offin, M. D.; Rizvi, H.; Tenet, M.; Ni, A.; Sanchez Vega, F.; Kris, M. G.; Rudin, C. M.; Riely, G. J.; Yu, H. A.; Hellmann, M. D.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • PD-L1 expression, tumor mutation burden and response to immune checkpoint blockade in patients with HER2-mutant lung cancers
    Meeting Abstract

    Lai, W. C. V.; Feldman, D. L.; Buonocore, D. J.; Brzostowski, E. B.; Rizvi, H.; Plodkowski, A. J.; Ni, A.; Sabari, J. K.; Offin, M. D.; Kris, M. G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save